Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02015065 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02015065: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT02015065 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02015065, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
Background: -Some people with wild-type gastrointestinal stromal tumors (WT-GIST) have a deficiency in one of their proteins called succinate dehydrogenase (SDH). Vandetanib is a cancer drug that has been approved to treat thyroid cancer and has been used with some success in other tumors that have a similar loss of SDH. Researchers want to see if this drug can also decrease tumor growth in people with WT-GIST. Objectives: -To test whether the study drug will benefit people with WT-GIST. Eligibility: -Adults and children 3 years old and older with WT-GIST. Design: * Researchers will test participants tumor tissue to confirm it is the wild type of GIST. * Participants will be screened with a medical history, physical exam, and blood tests. They will also have electrical recording of the heart (Eastern Cooperative Oncology Group (ECOG)) and scans of the tumor. * Participants will take the study drug in 28-day cycles. Their doctor will decide how many cycles they can complete. * They will take the study drug once every day and record it in a diary. * On Day 14, they will also visit their doctor to look for side effects. * Before cycles 2, 3 and 4, participants will have a physical exam, urine tests, blood pressure check, and blood tests. These tests will then be done periodically for as long as they are in the study. * Before cycle 4, scans will be done to check the size of the cancer. Most of these will be repeated every 3-6 cycles. * When they stop taking the study drug, participants will return to the clinic for a physical exam and blood tests.
Primary Outcome
Clinical activity will be assessed primarily by radiographic response of measurable disease using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease is at least a 20% increase in the sum of the d
Interventions
- DRUG Vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2013-12-14 |
| Est. Completion | 2019-12-10 |
| Phase | Phase 2 |
What the finished NCT02015065 record still lists
NCT02015065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Vandetanib is the first listed.
NCT02015065 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02015065 about?
NCT02015065 is a clinical study titled "Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors". Background: -Some people with wild-type gastrointestinal stromal tumors (WT-GIST) have a deficiency in one of their proteins called succinate dehydrogenase (SDH). Vandetanib is a cancer drug that has been approved to treat thyroid cancer and has been used with some success in other tumors that have...
What is the current status of trial NCT02015065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2013-12-14. Estimated completion is 2019-12-10.
What interventions are being tested in trial NCT02015065?
The interventions under investigation include: Vandetanib (DRUG).
Who is sponsoring clinical trial NCT02015065?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02015065's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI